TScan Therapeutics (TCRX) Projected to Post Earnings on Tuesday

TScan Therapeutics (NASDAQ:TCRX) is anticipated to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect TScan Therapeutics to post earnings of ($0.35) per share and revenue of $1.98 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 7:00 AM ET.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). The business had revenue of $3.08 million during the quarter, compared to the consensus estimate of $1.31 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%. On average, analysts expect TScan Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TScan Therapeutics Price Performance

NASDAQ TCRX traded down $0.01 during trading hours on Tuesday, reaching $1.24. The company’s stock had a trading volume of 470,070 shares, compared to its average volume of 491,643. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.06 and a current ratio of 7.06. The company’s 50-day moving average is $1.96 and its two-hundred day moving average is $1.73. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $6.23. The stock has a market cap of $70.09 million, a PE ratio of -1.13 and a beta of 1.00.

Institutional Trading of TScan Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its holdings in TScan Therapeutics by 6.0% in the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after buying an additional 9,676 shares during the period. JPMorgan Chase & Co. increased its position in shares of TScan Therapeutics by 8.5% in the second quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock worth $417,000 after acquiring an additional 22,642 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of TScan Therapeutics in the 2nd quarter valued at $78,000. Qube Research & Technologies Ltd acquired a new position in shares of TScan Therapeutics during the 2nd quarter valued at $99,000. Finally, Jane Street Group LLC acquired a new position in shares of TScan Therapeutics during the 2nd quarter valued at $309,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

Wall Street Analyst Weigh In

TCRX has been the topic of several research reports. Wedbush reiterated an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday, August 12th. Wall Street Zen raised TScan Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 12th. BTIG Research downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Wednesday, October 8th. Finally, Needham & Company LLC reduced their target price on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.20.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.